Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - terry+fry
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...
Published: 4/8/2024
|
Inventor(s):
Terry Fry
,
Crystal Mackall
,
Rimas Orentas
,
Haiying Qin
,
Waleed Haso
Keywords(s):
Acute Lymphoblastic Leukemia
,
ALL
,
BISPECIFIC
,
Bivalent
,
CAR
,
CD19
,
CD22
,
Diffuse Large B-Cell Lymphoma
,
DLBCL
,
Dual-Specific Chimeric Antigen Receptors
,
Fry
,
Oncology
,
Pediatric Leukemia
,
Pediatric Lymphoma
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia
Abstract: Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor which belongs in the receptor tyrosine kinase class III. FLT3 is expressed on the surface of many hematopoietic progenitor cells and plays an important role in hematopoietic stem/progenitor cell survival and proliferation. It is often overexpressed in acute lymphoblastic leukemia (ALL)...
Published: 5/22/2024
|
Inventor(s):
Dimiter Dimitrov
,
Weizhao Chen
,
Terry Fry
,
Christopher Chien
,
Haiying Qin
Keywords(s):
acute lymphocytic leukemia
,
acute myeloid leukemia
,
ALL
,
AML
,
CANCER
,
cancer therapeutic
,
chimeric antigen receptor (CAR)
,
Flt3
,
Monoclonal Antibody
Category(s):
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
Collaboration Sought > Licensing
Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)
Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually...
Published: 8/14/2024
|
Inventor(s):
Haiying Qin
,
Terry Fry
,
Crystal Mackall
Keywords(s):
Acute Lymphoblastic Leukemia
,
ALL
,
BICISTRONIC
,
CAR
,
CD19
,
CD22
,
Diffuse Large B-Cell Lymphoma
,
DLBCL
,
Dual-Specific Chimeric Antigen Receptors
,
Fry
,
Oncology
,
Pediatric Leukemia
,
Pediatric Lymphoma
Category(s):
TherapeuticArea > Oncology
,
Collaboration Sought > Licensing
,
Application > Therapeutics
,
Collaboration Sought > Collaboration
Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Abstract: Targeting the CD22 receptor of B-cells with chimeric antigen receptor (CAR)-T cells has been a promising new therapy to treat B-cell malignancies in clinical trials, inducing remission in 70% of patients with relapsed acute lymphoblastic leukemia (ALL). However, diminished CD22 expression on B-cell surface can lead to relapse and decreased...
Published: 8/14/2024
|
Inventor(s):
Dimiter Dimitrov
,
Zhongyu Zhu
,
Terry Fry
,
Sneha Ramakrishna
Keywords(s):
Acute Lymphoblastic Leukemia
,
ALL
,
B Cell
,
CAR
,
CAR-T
,
CD22
,
chimeric antigen receptor
,
Dimitrov
,
T cell
Category(s):
Application > Therapeutics
,
TherapeuticArea > Oncology
,
Collaboration Sought > Licensing